Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Loss and Comprehensive Loss

v3.25.0.1
Consolidated Statements of Loss and Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
EXPENSES      
Research and development $ 22,817 $ 15,814 $ 30,078
General and administrative 16,252 11,436 10,722
Total operating expenses 39,069 27,250 40,800
OTHER INCOME (EXPENSE)      
Interest income 2,356 825 199
Interest expense [note 9] (2,180) (2,853) (1,789)
Change in fair value of contingent consideration [note 6 and note 7] (621) (528)  
Loss on extinguishment of 2023 SVB convertible term loan [note 9] (283)    
Other expense (30) (9) 40
Total other expense (758) (2,565) (1,550)
Net Loss (39,827) (29,815) (42,350)
OTHER COMPREHENSIVE INCOME      
Net unrealized loss on securities 27    
Total other comprehensive income (loss) 27    
Comprehensive loss $ (39,800) $ (29,815) $ (42,350)
Basic net loss per common share [note 11 [i]] $ (1.24) $ (1.5) $ (4)
Diluted net loss per common share [note 11 [i]] $ (1.24) $ (1.5) $ (4)
Shares used in computation of basic net loss per common share [note 11 [i]] 32,071,146 19,827,354 10,593,034
Shares used in computation of Diluted net loss per common share [note 11 [i]] 32,071,146 19,827,354 10,593,034